FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2888894935> ?p ?o ?g. }

• W2888894935 endingPage "5338" @default.
• W2888894935 startingPage "5333" @default.
• W2888894935 abstract "Apatinib mesylate tablet in the treatment of advanced malignant melanoma Lingge Yang,1,2,* Huiyan Zhu,1,2,* Peng Luo,1,2 Shiqi Chen,1,2 Yu Xu,1,2 Chunmeng Wang1,2 1Department of Bone and Soft Tissue Sarcomas, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Observing and studying clinical efficacy and safety of apatinib mesylate tablet in the treatment of advanced malignant melanoma (MM). Methods: Retrospectively analyzing the clinical data of 22 patients with metastatic MM who had failed conventional chemotherapy from June 2016 to January 2018. All patients took 500 mg of apatinib mesylate tablets per day. The efficacy should be evaluated according to RECIST 1.1 criteria. Adverse events (AEs) should be graded according to NCI-CTCAE 4.0. Results: There were two cases of partial remission (PR), 11 of stable disease (SD) and nine of progressive disease (PD) in the 22 patients with advanced MM, where the objective remission rate (ORR) was 9.1% and the disease control rate (DCR) was 59.1%. The median progression-free survival (PFS) was 7.5 months, and the 6-month progression-free survival rate (PFR) was 54.7%. Six patients died and the overall survival (OS) was not reached. AEs were controllable and all were in Grade 1–3. Conclusion: Apatinib mesylate tablets have a certain curative effect on patients with malignant melanomas of Stage IV who failed conventional chemotherapy. Apatinib mesylate tablets at a daily dose of 500 mg are well tolerated by most patients. Keywords: apatinib, malignant melanoma, targeted therapy, adverse reaction, efficacy" @default.
• W2888894935 created "2018-09-07" @default.
• W2888894935 creator A5014829857 @default.
• W2888894935 creator A5017809307 @default.
• W2888894935 creator A5043564906 @default.
• W2888894935 creator A5045832304 @default.
• W2888894935 creator A5061742939 @default.
• W2888894935 creator A5083230588 @default.
• W2888894935 date "2018-08-01" @default.
• W2888894935 modified "2023-09-26" @default.
• W2888894935 title "Apatinib mesylate tablet in the treatment of advanced malignant melanoma" @default.
• W2888894935 cites W1816099873 @default.
• W2888894935 cites W1917632054 @default.
• W2888894935 cites W1993594227 @default.
• W2888894935 cites W1996917928 @default.
• W2888894935 cites W2007843735 @default.
• W2888894935 cites W2026788641 @default.
• W2888894935 cites W2037221770 @default.
• W2888894935 cites W2075868042 @default.
• W2888894935 cites W2077517114 @default.
• W2888894935 cites W2103152130 @default.
• W2888894935 cites W2104096707 @default.
• W2888894935 cites W2123363005 @default.
• W2888894935 cites W2128035403 @default.
• W2888894935 cites W2128542677 @default.
• W2888894935 cites W2190782500 @default.
• W2888894935 cites W2263279668 @default.
• W2888894935 cites W2276228008 @default.
• W2888894935 cites W2283064216 @default.
• W2888894935 cites W2338494814 @default.
• W2888894935 cites W2560367415 @default.
• W2888894935 cites W2591748434 @default.
• W2888894935 cites W2765775340 @default.
• W2888894935 doi "https://doi.org/10.2147/ott.s175507" @default.
• W2888894935 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6126500" @default.
• W2888894935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30214239" @default.
• W2888894935 hasPublicationYear "2018" @default.
• W2888894935 type Work @default.
• W2888894935 sameAs 2888894935 @default.
• W2888894935 citedByCount "9" @default.
• W2888894935 countsByYear W28888949352019 @default.
• W2888894935 countsByYear W28888949352020 @default.
• W2888894935 countsByYear W28888949352022 @default.
• W2888894935 countsByYear W28888949352023 @default.
• W2888894935 crossrefType "journal-article" @default.
• W2888894935 hasAuthorship W2888894935A5014829857 @default.
• W2888894935 hasAuthorship W2888894935A5017809307 @default.
• W2888894935 hasAuthorship W2888894935A5043564906 @default.
• W2888894935 hasAuthorship W2888894935A5045832304 @default.
• W2888894935 hasAuthorship W2888894935A5061742939 @default.
• W2888894935 hasAuthorship W2888894935A5083230588 @default.
• W2888894935 hasBestOaLocation W28888949351 @default.
• W2888894935 hasConcept C121608353 @default.
• W2888894935 hasConcept C126322002 @default.
• W2888894935 hasConcept C143998085 @default.
• W2888894935 hasConcept C16005928 @default.
• W2888894935 hasConcept C178790620 @default.
• W2888894935 hasConcept C185592680 @default.
• W2888894935 hasConcept C197934379 @default.
• W2888894935 hasConcept C2777583451 @default.
• W2888894935 hasConcept C2777658100 @default.
• W2888894935 hasConcept C2778729363 @default.
• W2888894935 hasConcept C2780194963 @default.
• W2888894935 hasConcept C2780668389 @default.
• W2888894935 hasConcept C2992053201 @default.
• W2888894935 hasConcept C3019892230 @default.
• W2888894935 hasConcept C502942594 @default.
• W2888894935 hasConcept C71924100 @default.
• W2888894935 hasConceptScore W2888894935C121608353 @default.
• W2888894935 hasConceptScore W2888894935C126322002 @default.
• W2888894935 hasConceptScore W2888894935C143998085 @default.
• W2888894935 hasConceptScore W2888894935C16005928 @default.
• W2888894935 hasConceptScore W2888894935C178790620 @default.
• W2888894935 hasConceptScore W2888894935C185592680 @default.
• W2888894935 hasConceptScore W2888894935C197934379 @default.
• W2888894935 hasConceptScore W2888894935C2777583451 @default.
• W2888894935 hasConceptScore W2888894935C2777658100 @default.
• W2888894935 hasConceptScore W2888894935C2778729363 @default.
• W2888894935 hasConceptScore W2888894935C2780194963 @default.
• W2888894935 hasConceptScore W2888894935C2780668389 @default.
• W2888894935 hasConceptScore W2888894935C2992053201 @default.
• W2888894935 hasConceptScore W2888894935C3019892230 @default.
• W2888894935 hasConceptScore W2888894935C502942594 @default.
• W2888894935 hasConceptScore W2888894935C71924100 @default.
• W2888894935 hasLocation W28888949351 @default.
• W2888894935 hasLocation W28888949352 @default.
• W2888894935 hasLocation W28888949353 @default.
• W2888894935 hasLocation W28888949354 @default.
• W2888894935 hasOpenAccess W2888894935 @default.
• W2888894935 hasPrimaryLocation W28888949351 @default.
• W2888894935 hasRelatedWork W2403708353 @default.
• W2888894935 hasRelatedWork W2403753987 @default.
• W2888894935 hasRelatedWork W2888894935 @default.
• W2888894935 hasRelatedWork W2945881045 @default.
• W2888894935 hasRelatedWork W2985220689 @default.
• W2888894935 hasRelatedWork W3029070866 @default.
• W2888894935 hasRelatedWork W3030835015 @default.
• W2888894935 hasRelatedWork W3036916953 @default.

• next